227 related articles for article (PubMed ID: 34106364)
1. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.
Gonçalves E
Eur J Health Econ; 2022 Mar; 23(2):155-163. PubMed ID: 34106364
[TBL] [Abstract][Full Text] [Related]
2. Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment.
Gonçalves E
Eur J Health Econ; 2020 Apr; 21(3):311-320. PubMed ID: 31919703
[TBL] [Abstract][Full Text] [Related]
3. New Models for the Evaluation of Specialized Medicinal Products: Beyond Conventional Health Technology Assessment and Pricing.
Pani L; Becker K
Clin Drug Investig; 2021 Jun; 41(6):529-537. PubMed ID: 34014509
[TBL] [Abstract][Full Text] [Related]
4. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
Ronco V; Dilecce M; Lanati E; Canonico PL; Jommi C
J Pharm Policy Pract; 2021 Mar; 14(1):30. PubMed ID: 33741076
[TBL] [Abstract][Full Text] [Related]
5. Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England.
Ten Ham RMT; Frederix GWJ; Wu O; Goettsch W; Leufkens HGM; Klungel OH; Hoekman J
Value Health; 2022 Mar; 25(3):390-399. PubMed ID: 35227451
[TBL] [Abstract][Full Text] [Related]
6. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare.
Jönsson B; Hampson G; Michaels J; Towse A; von der Schulenburg JG; Wong O
Eur J Health Econ; 2019 Apr; 20(3):427-438. PubMed ID: 30229376
[TBL] [Abstract][Full Text] [Related]
7. Market access pathways for cell therapies in France.
Rémuzat C; Toumi M; Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
[TBL] [Abstract][Full Text] [Related]
8. Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers.
Qiu T; Liang S; Wang Y; Dussart C; Borissov B; Toumi M
Front Public Health; 2021; 9():754482. PubMed ID: 34900902
[TBL] [Abstract][Full Text] [Related]
9. Pricing and Market Access Challenges in the Era of One-Time Administration Cell and Gene Therapies.
Sabatini MT; Xia T; Chalmers M
Pharmaceut Med; 2022 Oct; 36(5):265-274. PubMed ID: 35994198
[TBL] [Abstract][Full Text] [Related]
10. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
11. Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries.
Rejon-Parrilla JC; Espin J; Garner S; Kniazkov S; Epstein D
Front Pharmacol; 2023; 14():1199500. PubMed ID: 38089054
[No Abstract] [Full Text] [Related]
12. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
Iglesias-López C; Agustí A; Vallano A; Obach M
Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
[TBL] [Abstract][Full Text] [Related]
13. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
14. PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.
Benisheva-Dimitrova T; Sidjimova D; Cherneva D; Kralimarkov N
Int J Technol Assess Health Care; 2017 Jan; 33(3):365-370. PubMed ID: 28831942
[TBL] [Abstract][Full Text] [Related]
15. Challenges and opportunities for access to Advanced Therapy Medicinal Products in Brazil.
Sachetti CG; Barbosa A; de Carvalho ACC; Araujo DV; da Silva EN
Cytotherapy; 2024 Mar; ():. PubMed ID: 38639672
[TBL] [Abstract][Full Text] [Related]
16. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
17. What are the Changes in 2023 for Access to Advanced Therapy Medicinal Products (ATMPs) in France?
Bartos B
Eur J Health Law; 2024 Jan; 31(2):187-208. PubMed ID: 38280386
[TBL] [Abstract][Full Text] [Related]
18. Critical Reflections on Reimbursement and Access of Advanced Therapies.
Simoens S; De Groote K; Boersma C
Front Pharmacol; 2022; 13():771966. PubMed ID: 35662719
[No Abstract] [Full Text] [Related]
19. TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases.
Annemans L; Makady A
Orphanet J Rare Dis; 2020 May; 15(1):127. PubMed ID: 32456653
[TBL] [Abstract][Full Text] [Related]
20. Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries.
Gozzo L; Romano GL; Romano F; Brancati S; Longo L; Vitale DC; Drago F
Front Pharmacol; 2021; 12():755052. PubMed ID: 34690785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]